Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Leuk Lymphoma. 2016 Aug 11;58(4):923–931. doi: 10.1080/10428194.2016.1213823

Figure 4.

Figure 4.

Ganetespib reduces the percentage of EBV-infected cells, but not the level of EBV DNA, in the blood in a patient with hydroa vaccinforme and markedly elevated levels of EBV in the blood. A. PBMCs were isolated from blood, fluorescence in situ hybridization was performed using an EBV DNA probe, and the percentage of EBV infected cells was calculated. B. EBV DNA PCR was performed on peripheral whole blood from the patient before, during, and after ganetespib treatment. The dose of ganetespib (G) is indicated as mg/M2 (e.g. G60 is ganetespib 60 mg/M2). Arrows show doses of the drug. C. Peripheral blood mononuclear cells obtained before, and two days after, receiving 150 mg/M2 of ganetespib were sorted into Vβ5.1+CD4+ (+) and V β5.1−CD4+ (−) populations. Lysates obtained from equivalent numbers of cells from the two populations were run on gels and immunoblotting was performed with antibodies to HSP70 and β-actin.